Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke

by stemedica admin | Jan 18, 2023 | Clinical Trials

SAN DIEGO, California – January 19, 2023. Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant, allogeneic mesenchymal stem cells (itMSC), announced today that it has initiated its “PHASE IIB/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,...

DARIUS ANDERSON TO JOIN STEMEDICA BOARD OF DIRECTORS

by stemedica admin | Mar 30, 2022 | Company Initiatives

Respected and seasoned business leader, investor and political strategist offers multiple talents to stem cell technologies company SAN DIEGO, March 30, 2022 /PRNewswire/ — Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based...

Mesenchymal stem cells in the treatment of severe COVID-19

by stemedica admin | Sep 20, 2021 | Publications

Santosh Kesari1,2*, Gregory C. Kasper3*, Lev Verkh4 , Terese C. Hammond5 , Marla L. Matal3 , Jay W. Hammerling3 , Nikolai Tankovich4 , Adrianus P. Lim3 , Kevin H. Zhao3 , Tifany Juarez1 , Roberta E. Redfern3 , Jaya M. Gill6 , Natsuko Nomura1 , Audrey Hiemer1 , Annie...

StemProtein Awarded U.S. Patent for Biodegradable Microneedle Device

by stemedica admin | Aug 22, 2021 | Company Initiatives

Dissolvable Needles Allow Dermis Delivery of Proteins and Large Molecules SAN DIEGO — August 23, 2021 — StemProtein, LLC (a subsidiary of Stemedica Cell Technologies, Inc.) a leading manufacturer of physiologically balanced growth factors, exosomes, and...

Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with Moderate to Severe ARDS Using GMP, Allogeneic, Bone Marrow-Derived, Ischemic-Tolerant Mesenchymal Stem Cells

by stemedica admin | Aug 5, 2021 | Clinical Trials

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ — Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announces enrollment of patients for its...